ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2067

Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors

Ilke Coskun Benlidayi1, Meghna Lama2, Oladipo Kunle Afolayan2, Meera Shah3, Manali Sarkar4, Tamar Rubinstein5, Aleksandra Opinc-Rosiak6, Rada Miskovic7, Marcin Milchert8, Dimitri Luz Felipe da Silva9, Samuel Katsuyuki Shinjo10, Elena Nikiphorou11, Ioannis Parodis12, Vincenzo Venerito13, Vikas Agarwal14 and Latika Gupta15, 1Cukurova University, Adana, Turkey, 2The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, 3Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, 4Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, 5Albert Einstein College of Medicine, White Plains, NY, 6Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland., Lodz, Poland, 7University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, 8Pomeranian Medical University in Szczecin, Szczecin, Poland, 9University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, 10Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 11King's College London, London, United Kingdom, 12Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 13Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, 14Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 15School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom

Meeting: ACR Convergence 2025

Keywords: Comorbidity, Myopathies, Myositis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This study aimed to evaluate the patterns of comorbidities across IIM subsets, identify predictors of physical and mental comorbidities, and characterize comorbidity clusters.

Methods: This cross-sectional study used data from the Collating the Voices of Patients with Autoimmune Diseases study. Adults with specialist-diagnosed, self-reported IIMs were included. The validated Functional Comorbidities Index (FCI) was used to collect information on comorbidities. Subgroup comparisons were conducted across IIM subtypes. Descriptive statistics were performed and binary logistic regression was used to identify predictors of mental and physical health comorbidities. Hierarchical cluster analysis was applied to derive composite comorbidity clusters using R.

Results: Of 14,902 respondents, 1,209 IIM patients (69.6% female) were included [Fig.1A, 1B], with a median age and disease duration of 60 and 17 years, respectively (Table 1). The most common comorbidities were mental health conditions (32.1%), cardiovascular diseases (32.0%), and musculoskeletal disorders (23.3%). Mental (41.4%) and musculoskeletal (45.2%) comorbidities were most common in overlap myositis (OM). Cardiovascular conditions were most common in inclusion body myositis (IBM) (45.2%) [Fig.1C]. Predictors of mental health comorbidities included older age (OR:0.98; 95%CI=0.96-0.99), high Human Development Index (HDI) (OR:4.35; 95%CI=1.72-1.75), and alcohol intake (2-4 times/month) (OR:0.44; 95%CI=0.24-0.79). Predictors of physical health comorbidities were older age (OR:1.05; 95%CI=1.02-1.07), high HDI (OR:5.32; 95%CI=1.26-22.39), alcohol intake (2-4 times/month) (OR:0.45; 95%CI=0.23-0.90), and disease damage (OR:1.13; 95%CI=1.01-1.26). Hierarchical cluster analysis identified 3 comorbidity clusters. Cluster 1 was characterized by Hispanic ethnicity, lower HDI, and low multimorbidity, with notable immune-mediated necrotizing myopathies representation but limited variance. Cluster 2 was male-dominated, had very high HDI and moderate mental and physical comorbidity levels, and included the highest proportion of IBM and polymyositis. Cluster 3 showed the highest multimorbidity burden, dominated by dermatomyositis and anti-synthetase syndrome.

Conclusion: Comorbidities vary across IIM subtypes. Older age and high HDI predict both mental and physical health comorbidities, while higher disease damage predicts physical health comorbidity. Comorbidity clusters reveal distinct IIM subtype distributions, highlighting subtype-specific comorbidity patterns that may guide personalized clinical management.

Supporting image 1Fig.1: A- Flowchart depicting inclusion of participants; B- World map showing country-wise distribution of IIM respondents; C- Distribution of comorbidities across IIM subtypes

Supporting image 2Fig.2: A- Hierarchical cluster analysis in IIMs; B- Distribution of IIM subtypes in different clusters

Supporting image 3Table 1: Characteristics of study sample


Disclosures: I. Coskun Benlidayi: None; M. Lama: None; O. Afolayan: None; M. Shah: None; M. Sarkar: None; T. Rubinstein: None; A. Opinc-Rosiak: None; R. Miskovic: None; M. Milchert: None; D. Luz Felipe da Silva: AbbVie/Abbott, 5, 6, Boehringer-Ingelheim, 5, 6, Eli Lilly, 5, 6, Galderma, 5, 6, Janssen, 5, 6, Leo Pharma, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Sanofi, 5, 6, UCB, 5, 6; S. Shinjo: None; E. Nikiphorou: AbbVie/Abbott, 1, 2, 6, Alfasigma, 1, 6, Eli Lilly, 1, 2, 5, 6, Fresenius, 1, 6, Galapagos, 1, 6, Gilead, 1, 6, Novartis, 1, 2, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 2, 6; I. Parodis: Amgen, 5, 6, AstraZeneca, 5, 6, Aurinia, 5, BMS, 5, Eli Lilly, 5, F. Hoffman-La Roche Ltd, 5, 6, Gilead, 6, GSK, 5, 6, Janssen, 6, Novartis, 6, Otsuka, 5, 6, UCB, 2, 5; V. Venerito: None; V. Agarwal: None; L. Gupta: None.

To cite this abstract in AMA style:

Coskun Benlidayi I, Lama M, Afolayan O, Shah M, Sarkar M, Rubinstein T, Opinc-Rosiak A, Miskovic R, Milchert M, Luz Felipe da Silva D, Shinjo S, Nikiphorou E, Parodis I, Venerito V, Agarwal V, Gupta L. Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patterns-of-comorbidity-in-idiopathic-inflammatory-myopathies-a-cross-sectional-analysis-of-disease-burden-and-risk-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-comorbidity-in-idiopathic-inflammatory-myopathies-a-cross-sectional-analysis-of-disease-burden-and-risk-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology